Search
Prime Medicine Inc
PRMEAdd to Watchlist
3.180USD
+0.050+1.60%
Close 09-11 16:00（ET）
576.55MMarket Cap
LossP/E TTM
Prime Medicine Inc (PRME) Stock Price Target & Forecast
Analyst Rating
Based on 14 analysts giving stock ratings to Prime Medicine Inc in the past month.
Buy
4 Strong Buy
7 Buy
3 Hold
0 Sell
0 Strong Sell
Target Price
7.114USD+127.27%
PRME Analyst Recommendation Trends
In the current month, PRME has received 7 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. PRME average Analyst price target in the last month is 7.114.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
4
4
4
4
4
3
3
7
7
6
5
5
5
4
4
3
3
3
4
4
4
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
14
13
13
13
13
11
11
PRME Analyst Rating for Peer Comparison
Updated: Sep 13, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, PRME EPS is projected to reach -0.246 in FY2026Q3, following reported EPS of -0.238 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.25
-0.25
-0.26
-0.25
-0.23
Actual
-0.26
-0.28
-0.24
--
--
Surprise
-3.37%
-10.76%
+7.68%
--
--
FAQs
What is Prime Medicine Inc's expected revenue for the next quarter?
Prime Medicine Inc's expected revenue is 981.75K.
What is Prime Medicine Inc's price target?
Analysts forecast that Prime Medicine Inc's price target is USD 7.11, with the highest forecast at USD 11.00 and the lowest forecast at USD 4.25.
How have Prime Medicine IncPRME's recent earnings per share performed?
The market expectation was USD -0.24, while Prime Medicine IncPRME's earnings per share (EPS) for the previous quarter was USD -0.28. EPS for the next quarter is expected at USD -0.25.
What is the analyst rating for Prime Medicine Inc?
Based on the ratings of Prime Medicine Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.